Now Recruiting Patient Partners for our Rare Disease Registry Request for Proposals Evaluation Panel
In March 2025, Canada’s Drug Agency launched a funding opportunity for rare disease registries to enhance their capability and implement improvement initiatives to support decision-making in Canada related to drugs for rare diseases.
Canada’s Drug Agency Announces New 5-Year Strategic Plan
Canada’s Drug Agency announces a new 5-year strategic plan, Insight to Impact 2025–2030.
New Pan-Canadian Recommendations for Newborn Screening in Canada
Canada’s Drug Agency has published new guidance to support newborn screening programs in Canada, which play an important role in the early diagnosis of serious conditions and rare diseases.
This guidance was developed by the Newborn Screening Advisory Panel to support the National Strategy for Drugs for Rare Diseases and builds on prior newborn screening work in Canada.